Signify Bio, a Dallas, TX-based biotechnology firm harnessing the human physique for the manufacturing of in situ protein therapeutics, raised $15M in preliminary funding.
The spherical was led by Actium Group with participation from the Gates Basis Strategic Funding Fund, Danaher Ventures LLC, a subsidiary of Danaher Company, Eli Lilly and Firm, and BrightEdge, the American Most cancers Society’s (ACS) enterprise capital arm.
The corporate intends to make use of the funds to develop operations and its R&D efforts.
Signify Bio is a biotechnology firm enhancing the event of in situ protein therapeutics by leveraging the human physique’s pure skill to provide proteins. Guided by its mission to create customized medicines for all, it combines the precision of sign peptide engineered management with the pace and flexibility of mRNA encoded design. The corporate’s SEND platform and iPhos lipid nanoparticles allow focused and localized supply of therapeutic proteins, addressing unmet wants throughout numerous ailments.
The administration workforce contains:
- Daniel J. Siegwart, Ph.D., Co-founder and Chief Scientific Advisor, Director of the Program in Genetic Drug Engineering at UT Southwestern, Professor and W. Ray Wallace Distinguished Chair in Molecular Oncology Analysis, Departments of Biomedical Engineering and Biochemistry at UT Southwestern, Co-founder of ReCode Therapeutics;
- RA Session II, Co-founder, President, and Chief Govt Officer, former President, CEO, and Founding father of Taysha Gene Therapies and former Chief Enterprise Officer of the gene remedy subsidiaries of BridgeBio, former Board Member of ReCode Therapeutics;
- Lukas J. Farbiak, Ph.D., Co-founder and Chief Know-how Advisor, Assistant Professor, Departments of Biomedical Engineering and Biochemistry at UT Southwestern;
- David Morrissey, Ph.D., Chief Scientific Officer, former Vice President, Head RNA Accelerator at Pfizer and Senior Vice President, Platform & Supply Know-how at Intellia Therapeutics;
- Morag Stewart, Ph.D., Vice President of Translational Biology, former Senior Director, RNA Medicines at Pfizer Facilities for Therapeutic Innovation and Head of Exploratory Biology at Flagship Pioneering.
FinSMEs
05/06/2025
